Pharos iBio Statistics

Total Valuation

Pharos iBio has a market cap or net worth of KRW 118.46 billion. The enterprise value is 100.39 billion.

Market Cap	118.46B
Enterprise Value	100.39B

Important Dates

The last earnings date was Tuesday, March 31, 2026.

Earnings Date	Mar 31, 2026
Ex-Dividend Date	n/a

Share Statistics

Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 0.14% in one year.

Current Share Class	12.95M
Shares Outstanding	12.95M
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	-0.05%
Owned by Insiders (%)	32.95%
Owned by Institutions (%)	1.93%
Float	8.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	8.51
P/TBV Ratio	8.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.33
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.00

Financial Position

The company has a current ratio of 18.96, with a Debt / Equity ratio of 0.57.

Current Ratio	18.96
Quick Ratio	18.71
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	-0.95
Interest Coverage	-181.01

Financial Efficiency

Return on equity (ROE) is -66.12% and return on invested capital (ROIC) is -35.42%.

Return on Equity (ROE)	-66.12%
Return on Assets (ROA)	-29.06%
Return on Invested Capital (ROIC)	-35.42%
Return on Capital Employed (ROCE)	-40.41%
Weighted Average Cost of Capital (WACC)	2.87%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.01% in the last 52 weeks. The beta is -0.22, so Pharos iBio's price volatility has been lower than the market average.

Beta (5Y)	-0.22
52-Week Price Change	+53.01%
50-Day Moving Average	9,473.20
200-Day Moving Average	7,523.63
Relative Strength Index (RSI)	49.62
Average Volume (20 Days)	319,330

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-20.32M
Operating Income	-11.51B
Pretax Income	-10.76B
Net Income	-10.76B
EBITDA	-10.67B
EBIT	-11.51B
Earnings Per Share (EPS)	-831.00

Full Income Statement

Balance Sheet

The company has 26.01 billion in cash and 7.94 billion in debt, with a net cash position of 18.07 billion or 1,395.73 per share.

Cash & Cash Equivalents	26.01B
Total Debt	7.94B
Net Cash	18.07B
Net Cash Per Share	1,395.73
Equity (Book Value)	13.93B
Book Value Per Share	1,076.25
Working Capital	25.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.35 billion and capital expenditures -15.22 million, giving a free cash flow of -8.36 billion.

Operating Cash Flow	-8.35B
Capital Expenditures	-15.22M
Depreciation & Amortization	837.49M
Net Borrowing	18.84B
Free Cash Flow	-8.36B
FCF Per Share	-645.96

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Pharos iBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.14%
Shareholder Yield	-0.14%
Earnings Yield	-9.08%
FCF Yield	-7.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2